Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidutolimod plus Cemiplimab in Advanced or Metastatic Cancers
2023-507344-36-01Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and vidutolimod in cancer, Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (cSCC) and 3 more, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective Response Rate (ORR). Started Jan 2024; status: completed.
02
Drugs
cemiplimabvidutolimod
03
Conditions
cancerMerkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-507344-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507344-36-01.